Compare · AZN vs IMNN
AZN vs IMNN
Side-by-side comparison of AstraZeneca PLC (AZN) and Imunon Inc. (IMNN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and IMNN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $542.54B, about 70939.8x IMNN ($7.6M).
- Over the past year, AZN is down 7.1% and IMNN is down 86.9% - AZN leads by 79.8 points.
- AZN has been more active in the news (8 items in the past 4 weeks vs 6 for IMNN).
- AZN has more recent analyst coverage (25 ratings vs 0 for IMNN).
- Company
- AstraZeneca PLC
- Imunon Inc.
- Price
- $174.90-1.68%
- $1.83-8.04%
- Market cap
- $542.54B
- $7.6M
- 1M return
- -5.32%
- -21.46%
- 1Y return
- -7.11%
- -86.88%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- News (4w)
- 8
- 6
- Recent ratings
- 25
- 0
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest AZN
- Officer Sharma Mani was granted 1 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,263 units (SEC Form 4)
- SEC Form 6-K filed by AstraZeneca PLC
- TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
- NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
- Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
Latest IMNN
- SEC Form S-8 filed by Imunon Inc.
- SEC Form 8-K filed by Imunon Inc.
- Executive Chairman of Board Tardugno Michael H was granted 4,089 shares, increasing direct ownership by 47% to 12,838 units (SEC Form 4)
- President and CEO Lindborg Stacy was granted 1,593 shares, increasing direct ownership by 44% to 5,235 units (SEC Form 4)
- Imunon Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- IMUNON Announces Up to $10 Million Cash Financing
- Executive Chairman of Board Tardugno Michael H was granted 3,484 shares, increasing direct ownership by 66% to 8,749 units (SEC Form 4)
- Director Pellizzari Christine A was granted 5,557 shares, increasing direct ownership by 215% to 8,142 units (SEC Form 4)
- Director Dentzer James E was granted 11,148 shares, increasing direct ownership by 292% to 14,963 units (SEC Form 4)
- Director Braun Donald P was granted 5,011 shares, increasing direct ownership by 116% to 9,319 units (SEC Form 4)